中石化(00386.HK)成立醫用衛生材料研究所
中石化(00386.HK)發布消息指,中石化所屬北京化工研究院近日正式成立醫用衛生材料研究所,研究所的成立,將加快中國醫用衛生關鍵核心材料的技術開發,保障國內生物醫藥產業鏈安全,推動產業升級,助力國家醫用衛生材料核心技術自立自強目標實現。
該研究所將以解決制約中國醫用材料發展的瓶頸問題為導向,聚焦關鍵核心難題並創新科研體制機制,冀解決制約醫用材料產業發展的共性關鍵技術,開發出一批示範性專項成套技術。下一步,醫用衛生材料研究所將聯合醫衛行業的相關龍頭企業,搭建醫衛材料的全產業鏈協同創新產業聯盟,建設中石化醫用衛生材料創新研發平台,推動中石化現有醫衛產品快速擴展市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.